Skip to main content

Table 3 Comparison of characteristics among stage III and stage IV long-term survivors according to OS groups

From: Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients

Groups

Stage III

Stage IV

Variables

3 ≤ OS < 5

5 ≤ OS (tumor +)

5 ≤ OS (tumor -): CR

P value

3 ≤ OS < 5

5 ≤ OS (tumor +)

5 ≤ OS (tumor -): CR

P value

No. (% of the all stage III or IV patients)

13 (7.9)

12 (7.3)

12 (7.3)

 

29 (10.4)

17 (6.1)

5 (1.8)

 

Median OS

1405

2238**

2876**

< 0.01

1368

2503**

2643**

< 0.01

(Range) – days

(1097-1770)

(1836-3315)

(2271-4250)

 

(1109-1791)

(1933-3862)

(2160-4525)

 

Age (Median; Range) – yr.

69.0; 50-78

65.5; 54-79

63.5; 41-79

0.47

66; 37-89

67; 41-76

56; 36-69

0.21

Sex-no.

 Male

10

8

11

0.33

14

12

4

0.20

 Female

3

4

1

 

15

5

1

 

Smoking status

 Current

4

4

8

0.18

9

6

4

0.15

 Previous

4

6

3

 

6

6

1

 

 Never

5

2

1

 

14

5

0

 

 BMI

21.9 ± 2.97

23.4 ± 4.1

21.2 ± 1.85

0.24

23.0 ± 3.7

21.7 ± 2.5

19.4 ± 2.7

0.10

Complication

 +; no. (%)

11 (85%)

7 (58%)

6 (50%)

0.16

12

7

3

0.73

 -; no. (%)

2 (15%)

5 (42%)

6 (50%)

 

17

10

2

 

 Type of complication # – no.

   

0.74

   

0.62

 COPD

3

4

1

 

3

0

1

 

 Pulmonary fibrosis

2

1

0

 

0

0

0

 

 Diabetes mellitus

2

3

2

 

5

1

2

 

 Heart and aortic diseases

0

2

1

 

4

1

1

 

 Previous cancer treatment

3

1

1

 

0

1

0

 

 Occupation $

   

0.56

   

0.60

 Manager, Professional and Technician

2

1

4

 

8

7

2

 

 Skilled agricultural, and crafts and related trades

5

4

4

 

8

6

2

 

 Others including no regular occupation

6

7

4

 

13

4

1

 

 Lymphocyte counts in blood (no. / μl; mean ± SD)

1,785 ± 538

2,249 ± 803

2,182 ± 634

0.29

1,735 ± 503

1,988 ± 521

2,413 ± 710*

< 0.05

Histological characteristics of tumor – no. (%)

 Adenocarcinoma

8

8

4

0.37

23

14

4

0.16

 Large cell carcinoma

0

0

0

 

0

0

1

 

 Squamous cell carcinoma

4

1

4

 

2

1

0

 

 Not otherwise specified

1

3

2

 

2

0

0

 

 Other cell types

0

0

2

 

2

2

0

 

EGFR mutation status

   

0.03

   

0.28

Positive/Negative/Unknown

3 / 2 / 8

1 / 6 / 5

0 / 1 / 11

 

7 / 6 / 16

6 / 4 / 7

0 / 3 /2

 

ECOG performance status

 1

5

7

5

0.57

15

7

0

0.10

 0

8

5

7

 

14

10

5

 

 Primary tumor diameter (mm; mean ± SD)

38.7 ± 22.9

40.0 ± 15.4

30.0 ± 18.6

0.34

39.6 ± 13.6

29.6 ± 14.4

17.5 ± 13.2**

< 0.01

N factor – no.

 N3

6

0

4

0.052

13

2

0

< 0.05

 N2

6

11

5

 

8

10

1

 

 N1

0

0

2

 

3

0

1

 

 N0

1

1

1

 

5

5

3

 

M factor – no.

 M1c

    

6

3

0

0.28

 M1b

    

5

6

3

 

 M1a

    

18

8

2

 

 Total metastatic number at initial diagnosis (no.; mean ± SD)

-

-

-

 

6.6 ± 4.1

5.2 ± 3.8

0.6 ± 0.6**

< 0.05

  1. BMI: body mass index, COPD: chronic obstructive pulmonary disease, EGFR: epidermal growth factor receptor, ECOG: Eastern Cooperative Oncology Group, * : P < 0.05 and **: P < 0.01 compared with the 3 ≤ OS < 5 group. + denotes existence of any complication before treatment. -denotes existence of no complication before treatment. #; Some patients had several complications. $; The International Standard Classification of Occupations (ISCO)-08 was used for this occupational classification. “Not otherwise specified” was based on a pathological determination, with the features being as follows. First, the tumor was pathologically diagnosed as NSCLC. Second, the NSCLC could not be classified into subgroups, due to the lack of positive findings on cytology, hematoxylin-eosin staining and/or immunohistochemical staining
  2. All significant P values are expressed in boldface, and not significant P values are expressed in plainface
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us